With access to biopsies and tissue blocks at different time points from individual case studies (patients A–D that progressed from IBD to CRC), we explored the expression status of RASS1A, RIPK2, AMPK, and YAP, and studied whether more profound changes were observed when CRC was compared to UC with no CRC. This evidence concerns the gene RIPK2 and colorectal carcinoma.